OTCMKTS:RSLS

ReShape Lifesciences Competitors

$4.50

+0.35 (+8.43 %)

(As of 04/12/2021 03:03 PM ET)

Add

Compare

Today's Range

$4.33

Now: $4.50▼

$4.50

50-Day Range

$4.10

MA: $5.02▼

$7.32

52-Week Range

$1.14

Now: $4.50▼

$14.00

Volume1,501 shs

Average Volume3,117 shs

Market Capitalization$27.75 million

P/E RatioN/A

Dividend YieldN/A

Beta2.03

ReShape Lifesciences (OTCMKTS:RSLS) Vs. ABT, MDT, SYK, ISRG, BDX, and BSX

Should you be buying RSLS stock or one of its competitors? Companies in the sub-industry of "health care equipment" are considered alternatives and competitors to ReShape Lifesciences, including Abbott Laboratories (ABT), Medtronic (MDT), Stryker (SYK), Intuitive Surgical (ISRG), Becton, Dickinson and (BDX), and Boston Scientific (BSX).

ReShape Lifesciences vs. Abbott Laboratories Stock

ReShape Lifesciences (OTCMKTS:RSLS) and Abbott Laboratories (NYSE:ABT) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their profitability, institutional ownership, dividends, risk, earnings, analyst recommendations and valuation.

Valuation and Earnings

This table compares ReShape Lifesciences and Abbott Laboratories' top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ReShape Lifesciences	$15.09 million	1.84	$-74,210,000.00	N/A	N/A
Abbott Laboratories	$31.90 billion	6.72	$3.69 billion	$3.24	37.36

Abbott Laboratories has higher revenue and earnings than ReShape Lifesciences.

Profitability

This table compares ReShape Lifesciences and Abbott Laboratories' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
ReShape Lifesciences	-314.18%	-186.31%	-101.10%
Abbott Laboratories	10.50%	18.19%	8.29%

Insider and Institutional Ownership

72.6% of Abbott Laboratories shares are held by institutional investors. 1.7% of Abbott Laboratories shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Risk & Volatility

ReShape Lifesciences has a beta of 2.03, meaning that its share price is 103% more volatile than the S&P 500. Comparatively, Abbott Laboratories has a beta of 0.83, meaning that its share price is 17% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings for ReShape Lifesciences and Abbott Laboratories, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ReShape Lifesciences	0	0	1	0	3.00
Abbott Laboratories	1	1	15	0	2.82

Abbott Laboratories has a consensus price target of $122.0556, indicating a potential upside of 0.84%. Given Abbott Laboratories' higher probable upside, analysts clearly believe Abbott Laboratories is more favorable than ReShape Lifesciences.

Summary

Abbott Laboratories beats ReShape Lifesciences on 10 of the 12 factors compared between the two stocks.

ReShape Lifesciences vs. Medtronic Stock

ReShape Lifesciences (OTCMKTS:RSLS) and Medtronic (NYSE:MDT) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, institutional ownership, risk, valuation, dividends, earnings and analyst recommendations.

Valuation & Earnings

This table compares ReShape Lifesciences and Medtronic's top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ReShape Lifesciences	$15.09 million	1.84	$-74,210,000.00	N/A	N/A
Medtronic	$28.91 billion	5.68	$4.79 billion	$4.59	26.53

Medtronic has higher revenue and earnings than ReShape Lifesciences.

Profitability

This table compares ReShape Lifesciences and Medtronic's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
ReShape Lifesciences	-314.18%	-186.31%	-101.10%
Medtronic	12.69%	9.71%	5.30%

Insider & Institutional Ownership

79.2% of Medtronic shares are owned by institutional investors. 0.5% of Medtronic shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Volatility & Risk

ReShape Lifesciences has a beta of 2.03, meaning that its stock price is 103% more volatile than the S&P 500. Comparatively, Medtronic has a beta of 0.7, meaning that its stock price is 30% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of current recommendations and price targets for ReShape Lifesciences and Medtronic, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ReShape Lifesciences	0	0	1	0	3.00
Medtronic	0	3	18	1	2.91

Medtronic has a consensus price target of $124.2692, indicating a potential upside of 2.04%. Given Medtronic's higher probable upside, analysts clearly believe Medtronic is more favorable than ReShape Lifesciences.

Summary

Medtronic beats ReShape Lifesciences on 11 of the 13 factors compared between the two stocks.

ReShape Lifesciences vs. Stryker Stock

ReShape Lifesciences (OTCMKTS:RSLS) and Stryker (NYSE:SYK) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, institutional ownership, risk, valuation, dividends, earnings and analyst recommendations.

Insider & Institutional Ownership

71.5% of Stryker shares are owned by institutional investors. 6.8% of Stryker shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares ReShape Lifesciences and Stryker's top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ReShape Lifesciences	$15.09 million	1.84	$-74,210,000.00	N/A	N/A
Stryker	$14.88 billion	6.37	$2.08 billion	$8.26	30.49

Stryker has higher revenue and earnings than ReShape Lifesciences.

Analyst Recommendations

This is a summary of current recommendations and price targets for ReShape Lifesciences and Stryker, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ReShape Lifesciences	0	0	1	0	3.00
Stryker	1	6	14	1	2.68

Stryker has a consensus price target of $234.6818, indicating a potential downside of 6.81%. Given Stryker's higher probable upside, analysts clearly believe Stryker is more favorable than ReShape Lifesciences.

Profitability

This table compares ReShape Lifesciences and Stryker's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
ReShape Lifesciences	-314.18%	-186.31%	-101.10%
Stryker	12.35%	20.94%	8.77%

Volatility & Risk

ReShape Lifesciences has a beta of 2.03, meaning that its stock price is 103% more volatile than the S&P 500. Comparatively, Stryker has a beta of 0.87, meaning that its stock price is 13% less volatile than the S&P 500.

Summary

Stryker beats ReShape Lifesciences on 11 of the 13 factors compared between the two stocks.

ReShape Lifesciences vs. Intuitive Surgical Stock

Intuitive Surgical (NASDAQ:ISRG) and ReShape Lifesciences (OTCMKTS:RSLS) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, institutional ownership, earnings, dividends, analyst recommendations, valuation and profitability.

Institutional & Insider Ownership

86.5% of Intuitive Surgical shares are owned by institutional investors. 1.6% of Intuitive Surgical shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Earnings and Valuation

This table compares Intuitive Surgical and ReShape Lifesciences' gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Intuitive Surgical	$4.48 billion	20.60	$1.38 billion	$9.95	78.32
ReShape Lifesciences	$15.09 million	1.84	$-74,210,000.00	N/A	N/A

Intuitive Surgical has higher revenue and earnings than ReShape Lifesciences.

Profitability

This table compares Intuitive Surgical and ReShape Lifesciences' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Intuitive Surgical	24.45%	12.08%	10.44%
ReShape Lifesciences	-314.18%	-186.31%	-101.10%

Analyst Ratings

This is a summary of current ratings and price targets for Intuitive Surgical and ReShape Lifesciences, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Intuitive Surgical	3	8	11	0	2.36
ReShape Lifesciences	0	0	1	0	3.00

Intuitive Surgical presently has a consensus price target of $750.9444, indicating a potential downside of 3.63%. Given Intuitive Surgical's higher probable upside, analysts plainly believe Intuitive Surgical is more favorable than ReShape Lifesciences.

Volatility & Risk

Intuitive Surgical has a beta of 0.98, meaning that its share price is 2% less volatile than the S&P 500. Comparatively, ReShape Lifesciences has a beta of 2.03, meaning that its share price is 103% more volatile than the S&P 500.

Summary

Intuitive Surgical beats ReShape Lifesciences on 10 of the 12 factors compared between the two stocks.

ReShape Lifesciences vs. Becton, Dickinson and Stock

Becton, Dickinson and (NYSE:BDX) and ReShape Lifesciences (OTCMKTS:RSLS) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, risk, dividends, valuation and analyst recommendations.

Profitability

This table compares Becton, Dickinson and and ReShape Lifesciences' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Becton, Dickinson and	5.11%	13.30%	5.60%
ReShape Lifesciences	-314.18%	-186.31%	-101.10%

Volatility & Risk

Becton, Dickinson and has a beta of 0.79, suggesting that its share price is 21% less volatile than the S&P 500. Comparatively, ReShape Lifesciences has a beta of 2.03, suggesting that its share price is 103% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent recommendations for Becton, Dickinson and and ReShape Lifesciences, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Becton, Dickinson and	0	6	7	0	2.54
ReShape Lifesciences	0	0	1	0	3.00

Becton, Dickinson and currently has a consensus price target of $281.5455, indicating a potential upside of 13.80%. Given Becton, Dickinson and's higher probable upside, equities research analysts plainly believe Becton, Dickinson and is more favorable than ReShape Lifesciences.

Institutional and Insider Ownership

83.2% of Becton, Dickinson and shares are held by institutional investors. 0.8% of Becton, Dickinson and shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares Becton, Dickinson and and ReShape Lifesciences' gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Becton, Dickinson and	$17.12 billion	4.20	$874 million	$10.20	24.26
ReShape Lifesciences	$15.09 million	1.84	$-74,210,000.00	N/A	N/A

Becton, Dickinson and has higher revenue and earnings than ReShape Lifesciences.

Summary

Becton, Dickinson and beats ReShape Lifesciences on 10 of the 12 factors compared between the two stocks.

ReShape Lifesciences vs. Boston Scientific Stock

ReShape Lifesciences (OTCMKTS:RSLS) and Boston Scientific (NYSE:BSX) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their institutional ownership, risk, dividends, profitability, analyst recommendations, earnings and valuation.

Analyst Ratings

This is a breakdown of current recommendations and price targets for ReShape Lifesciences and Boston Scientific, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ReShape Lifesciences	0	0	1	0	3.00
Boston Scientific	0	4	15	1	2.85

Boston Scientific has a consensus target price of $43.20, indicating a potential upside of 9.81%. Given Boston Scientific's higher probable upside, analysts clearly believe Boston Scientific is more favorable than ReShape Lifesciences.

Valuation & Earnings

This table compares ReShape Lifesciences and Boston Scientific's revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ReShape Lifesciences	$15.09 million	1.84	$-74,210,000.00	N/A	N/A
Boston Scientific	$10.74 billion	5.21	$4.70 billion	$1.58	24.90

Boston Scientific has higher revenue and earnings than ReShape Lifesciences.

Institutional & Insider Ownership

90.7% of Boston Scientific shares are owned by institutional investors. 0.7% of Boston Scientific shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares ReShape Lifesciences and Boston Scientific's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
ReShape Lifesciences	-314.18%	-186.31%	-101.10%
Boston Scientific	36.59%	11.77%	5.57%

Risk & Volatility

ReShape Lifesciences has a beta of 2.03, meaning that its stock price is 103% more volatile than the S&P 500. Comparatively, Boston Scientific has a beta of 0.87, meaning that its stock price is 13% less volatile than the S&P 500.

Summary

Boston Scientific beats ReShape Lifesciences on 11 of the 13 factors compared between the two stocks.